Pancrelipase + Placebo
ApprovedTerminated 3 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Exocrine Pancreatic Insufficiency (EPI)
Conditions
Exocrine Pancreatic Insufficiency (EPI)
Trial Timeline
Feb 25, 2020 → Mar 23, 2022
NCT ID
NCT03859869About Pancrelipase + Placebo
Pancrelipase + Placebo is a approved stage product being developed by AbbVie for Exocrine Pancreatic Insufficiency (EPI). The current trial status is terminated. This product is registered under clinical trial identifier NCT03859869. Target conditions include Exocrine Pancreatic Insufficiency (EPI).
What happened to similar drugs?
2 of 3 similar drugs in Exocrine Pancreatic Insufficiency (EPI) were approved
Approved (2) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03859869 | Approved | Terminated |
Competing Products
6 competing products in Exocrine Pancreatic Insufficiency (EPI)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pancrelipase in combination with Ensure Plus | Johnson & Johnson | Phase 1 | 29 |
| Pancrease MT 10.5, or MT 21 + Placebo for Pancrease MT 10.5 or MT 21 | Johnson & Johnson | Phase 3 | 40 |
| CREON | AbbVie | Approved | 35 |
| Creon IR + Creon® (DR/GR) | AbbVie | Phase 2 | 35 |
| Pancrelipase Capsules | AbbVie | Approved | 50 |
| Lipacreon | Viatris | Pre-clinical | 23 |